Thermo Fisher Scientific's stock plummeted 10.01% during intraday trading on Thursday, marking a significant decline following the release of its first-quarter 2026 financial results.
The medical equipment maker reported adjusted earnings per share of $5.44, beating the consensus estimate of $5.24, and revenue of $11.01 billion, surpassing expectations of $10.85 billion. Despite these positive headline numbers, the stock came under heavy selling pressure. Analysts attributed the decline to underperformance in key segments, with revenue from analytical instruments remaining flat and specialty diagnostics dipping slightly. The company also cited weak demand from academic and government customers in both the U.S. and China, with market conditions for its instruments business described as "below normal levels."
Furthermore, the company raised its full-year revenue guidance to a range of $47.3 billion to $48.1 billion, up from prior estimates, but the market reaction suggests this outlook may have been insufficient relative to expectations or already priced in. Broader market sentiment was also dented by geopolitical tensions related to the U.S.-Iran conflict, with executives warning that the situation could create "some modest level of inflationary pressure." This combination of segment-specific challenges and macroeconomic headwinds drove the sharp intraday decline.
Comments